iScience (Nov 2022)
Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals
- Erola Ainsua-Enrich,
- Núria Pedreño-Lopez,
- Carmen Bracke,
- Carlos Ávila-Nieto,
- María Luisa Rodríguez de la Concepción,
- Edwards Pradenas,
- Benjamin Trinité,
- Silvia Marfil,
- Cristina Miranda,
- Sandra González,
- Ruth Toledo,
- Marta Font,
- Susana Benet,
- Tuixent Escribà,
- Esther Jimenez-Moyano,
- Ruth Peña,
- Samandhy Cedeño,
- Julia G. Prado,
- Beatriz Mothe,
- Christian Brander,
- Nuria Izquierdo-Useros,
- Julia Vergara-Alert,
- Joaquim Segalés,
- Marta Massanella,
- Rosa María Benitez,
- Alba Romero,
- Daniel Molina-Morant,
- Julià Blanco,
- Bonaventura Clotet,
- Lourdes Mateu,
- María Luisa Pedro-Botet,
- Jorge Carrillo
Affiliations
- Erola Ainsua-Enrich
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Núria Pedreño-Lopez
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Carmen Bracke
- Infectious Diseases Department, Germans Trias i Pujol Hospital, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Carlos Ávila-Nieto
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- María Luisa Rodríguez de la Concepción
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Edwards Pradenas
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Benjamin Trinité
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Silvia Marfil
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Cristina Miranda
- Fight AIDS Foundation, Badalona, Catalonia 08916, Spain
- Sandra González
- Fight AIDS Foundation, Badalona, Catalonia 08916, Spain
- Ruth Toledo
- Fight AIDS Foundation, Badalona, Catalonia 08916, Spain
- Marta Font
- Fight AIDS Foundation, Badalona, Catalonia 08916, Spain
- Susana Benet
- Fight AIDS Foundation, Badalona, Catalonia 08916, Spain
- Tuixent Escribà
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Esther Jimenez-Moyano
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Ruth Peña
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Samandhy Cedeño
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Julia G. Prado
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain; Germans Trias i Pujol Research Institute (IGTP), Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Beatriz Mothe
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain
- Christian Brander
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Catalonia 08010, Spain; University of Vic, Central University of Catalonia, Vic, Catalonia 08500, Spain
- Nuria Izquierdo-Useros
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain; Germans Trias i Pujol Research Institute (IGTP), Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Julia Vergara-Alert
- Unitat mixta d’Investigació IRTA-UAB en Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), Universitat Autonoma de Barcelona, Bellaterra, Catalonia 08193, Spain; IRTA. Programa de Sanitat Animal. Centre de Recerca en Sanitat Animal (CReSA), Universitat Autònoma de Barcelona, Bellaterra, Catalonia 08193, Spain
- Joaquim Segalés
- Unitat mixta d’Investigació IRTA-UAB en Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), Universitat Autonoma de Barcelona, Bellaterra, Catalonia 08193, Spain; Departament de Sanitat i Anatomia animal, Facultat de Veterinaria, Universitat Autonoma de Barcelona, Bellaterra, Catalonia 08193, Spain
- Marta Massanella
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain
- Rosa María Benitez
- Infectious Diseases Department, Germans Trias i Pujol Hospital, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Alba Romero
- Infectious Diseases Department, Germans Trias i Pujol Hospital, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Daniel Molina-Morant
- Infectious Diseases Department, Germans Trias i Pujol Hospital, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain
- Julià Blanco
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain; Germans Trias i Pujol Research Institute (IGTP), Carretera Canyet s/n, Badalona, Catalonia 08916, Spain; University of Vic, Central University of Catalonia, Vic, Catalonia 08500, Spain
- Bonaventura Clotet
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain; Infectious Diseases Department, Germans Trias i Pujol Hospital, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain; Respiratory Diseases Networking Biomedical Research Center (CIBERes), Carlos III Health Institute, Madrid, Spain
- Lourdes Mateu
- Infectious Diseases Department, Germans Trias i Pujol Hospital, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain; Departament de Sanitat i Anatomia animal, Facultat de Veterinaria, Universitat Autonoma de Barcelona, Bellaterra, Catalonia 08193, Spain
- María Luisa Pedro-Botet
- Infectious Diseases Department, Germans Trias i Pujol Hospital, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain; Respiratory Diseases Networking Biomedical Research Center (CIBERes), Carlos III Health Institute, Madrid, Spain; Universitat Autónoma de Barcelona, Bellaterra, Catalonia 08193, Spain; Corresponding author
- Jorge Carrillo
- IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain; Germans Trias i Pujol Research Institute (IGTP), Carretera Canyet s/n, Badalona, Catalonia 08916, Spain; Corresponding author
- Journal volume & issue
-
Vol. 25,
no. 11
p. 105455
Abstract
Summary: Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) after three mRNA-1273 vaccine doses. PAD patients were classified based on their immunodeficiency: unclassified primary antibody-deficiency (unPAD, n = 9), common variable immunodeficiency (CVID, n = 12), combined immunodeficiency (CID, n = 1), and thymoma with immunodeficiency (TID, n = 1). unPAD patients and healthy controls (HCs, n = 10) developed similar vaccine-induced humoral responses after two doses. However, CVID patients showed reduced binding and neutralizing titers compared to HCs. Of interest, these PAD groups showed lower levels of Spike-specific IFN-γ-producing cells. CVID individuals also presented diminished CD8+T cells. CID and TID patients developed cellular but not humoral responses. Although the third vaccine dose boosted humoral responses in most PAD patients, it had limited effect on expanding cellular immunity. Vaccine-induced immune responses in PAD individuals are heterogeneous, and should be immunomonitored to define a personalized therapeutic strategies.
